Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Boehringer Ingelheim, in partnership with the WHO Foundation [an organisation set up to support the World Health Organization ...

The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis ...

Boehringer Ingelheim and Circle Pharma have entered a new research partnership and licence agreement to develop a new ...

With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy Ofev.

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare servic ...

The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...

Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

Find out how this could enhance access to quality healthcare, with an emphasis on mental health services for vulnerable populations.